ABIONYX Pharma SA ABNX.PA Stock
ABIONYX Pharma SA Price Chart
ABIONYX Pharma SA ABNX.PA Financial and Trading Overview
| ABIONYX Pharma SA stock price | 1.12 EUR |
| Previous Close | 1.26 EUR |
| Open | 1.29 EUR |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 1.28 - 1.31 EUR |
| 52 Week Range | 1.11 - 2.49 EUR |
| Volume | 33.12K EUR |
| Avg. Volume | 146.77K EUR |
| Market Cap | 36.99M EUR |
| Beta (5Y Monthly) | 0.227079 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.11 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.5 EUR |
ABNX.PA Valuation Measures
| Enterprise Value | N/A |
| Trailing P/E | N/A |
| Forward P/E | -4.16129 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 6.97907 |
| Price/Book (mrq) | 4.16129 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
ABIONYX Pharma SA Stock Price History
| Beta (5Y Monthly) | 0.227079 |
| 52-Week Change | -20.35% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.49 EUR |
| 52 Week Low | 1.11 EUR |
| 50-Day Moving Average | 1.69 EUR |
| 200-Day Moving Average | 1.84 EUR |
ABNX.PA Share Statistics
| Avg. Volume (3 month) | 146.77K EUR |
| Avg. Daily Volume (10-Days) | 82.07K EUR |
| Shares Outstanding | 28.18M |
| Float | N/A |
| Short Ratio | N/A |
| % Held by Insiders | 32.35% |
| % Held by Institutions | 11.94% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -79.24% |
| Operating Margin (ttm) | -77.35% |
| Gross Margin | 13.20% |
| EBITDA Margin | -76.73% |
Management Effectiveness
| Return on Assets (ttm) | N/A |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 5.3M EUR |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | 312.00% |
| Gross Profit (ttm) | 700K EUR |
| EBITDA | -4067000 EUR |
| Net Income Avi to Common (ttm) | -4200000 EUR |
| Diluted EPS (ttm) | -0.15 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | N/A |
| Total Cash Per Share (mrq) | N/A |
| Total Debt (mrq) | N/A |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | N/A |
| Book Value Per Share (mrq) | 0.31 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -3400000 EUR |
| Levered Free Cash Flow (ttm) | N/A |
Profile of ABIONYX Pharma SA
| Country | France |
| State | N/A |
| City | Balma |
| Address | 33 43 av. Georges Pompidou Bât. D2 |
| ZIP | 31130 |
| Phone | 33 5 62 24 97 06 |
| Website | https://abionyx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.
Q&A For ABIONYX Pharma SA Stock
What is a current ABNX.PA stock price?
ABIONYX Pharma SA ABNX.PA stock price today per share is 1.12 EUR.
How to purchase ABIONYX Pharma SA stock?
You can buy ABNX.PA shares on the Paris exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ABIONYX Pharma SA?
The stock symbol or ticker of ABIONYX Pharma SA is ABNX.PA.
Which industry does the ABIONYX Pharma SA company belong to?
The ABIONYX Pharma SA industry is Biotechnology.
How many shares does ABIONYX Pharma SA have in circulation?
The max supply of ABIONYX Pharma SA shares is 32.15M.
What is ABIONYX Pharma SA Price to Earnings Ratio (PE Ratio)?
ABIONYX Pharma SA PE Ratio is now.
What was ABIONYX Pharma SA earnings per share over the trailing 12 months (TTM)?
ABIONYX Pharma SA EPS is -0.11 EUR over the trailing 12 months.
Which sector does the ABIONYX Pharma SA company belong to?
The ABIONYX Pharma SA sector is Healthcare.
ABIONYX Pharma SA ABNX.PA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| CAC Small CS90 | 11739.13 EUR 12832.46 USD |
-0.74
|
— — | — — | — — | — - | — — |
| CAC Mid & Small MS190 | 14267.59 EUR 15596.4 USD |
-0.38
|
— — | — — | — — | — - | — — |
- {{ link.label }} {{link}}